Form 8-K - Current report:
SEC Accession No. 0001140361-22-040018
Filing Date
2022-11-04
Accepted
2022-11-04 16:39:58
Documents
14
Period of Report
2022-11-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc10043741_8k.htm   iXBRL 8-K 29577
2 EXHIBIT 99.1 brhc10043741_ex99-1.htm EX-99.1 157551
6 image01.jpg GRAPHIC 6484
  Complete submission text file 0001140361-22-040018.txt   344656

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ocup-20221104.xsd EX-101.SCH 3866
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ocup-20221104_lab.xml EX-101.LAB 22547
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ocup-20221104_pre.xml EX-101.PRE 16045
8 EXTRACTED XBRL INSTANCE DOCUMENT brhc10043741_8k_htm.xml XML 4087
Mailing Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335
Business Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335 248-681-9815
Ocuphire Pharma, Inc. (Filer) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34079 | Film No.: 221362823
SIC: 2834 Pharmaceutical Preparations